TY - JOUR
T1 - Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients
AU - Novo, Salvatore
AU - Maria, Dorobantu
AU - Livio, Dei Cas
AU - Ambrosio, Giuseppe
AU - Corrado, Tamburino
AU - Calin, Pop
AU - Dimitrios, Alexopolulus
AU - Silva, Cardoso
AU - Fernández, Romero
AU - Diaz, null
AU - Federico, Miccoli
AU - Marco, Agrusta
AU - Jorge, Salerno Uriarte
AU - Victor, Avenirovitch Kostenko
AU - Antonio, Castello
AU - Pio, Caso
AU - Maria, Dorobantu
AU - Aurora, Andrade
AU - Valentin, Sergeevich Moiseev
AU - Antonio, Raviele
AU - Tommaso, Cipolla
AU - Rosario, Evola
AU - Luciano, Fattore
AU - Antonio, Barsotti
AU - Boris, Mikhailovich Goloschekin
AU - Mircea, Cinteza
AU - Antonio, Fiscella
AU - Ioan, Manitiu
AU - Alexander, Yurievich Vishnevsky
AU - Dilek, Ural Komsuoglu
AU - Catalina, Arsenescu Georgescu
AU - Abram, Lvovich Syrkin
AU - Filippo, Marte
AU - Paolo, Di Pasquale
AU - Achille, Gaspardone
AU - Maurizio, Porcu
AU - Olena, Ankindinovna Koval
AU - Giancarlo, Marenzi
AU - Raffaele, Ferrante
AU - Luigi, Caliendo
AU - Dimitrios, Alexopolulus
AU - Serena, Bergerone
AU - Niccoló, Marchionni
AU - Giuseppe, De Nittis
AU - Bernardino, Tuccillo
AU - Igor, Petrovich Vakalyuk
AU - Sergey, Nikolaevich Tereschenko
AU - Mario, Orlandi
AU - Evgeniy, Mikhaylovich Nifontov
AU - Dominic, Ionescu
AU - Ludovico, Vasquez
AU - Yuriy, Borisovich Karpov
AU - Giuseppe, Ielasi
AU - Patrizia, Noussan
AU - Rita, Trinchero
AU - Florin, Ortan
AU - Cevat, Kirma
AU - Natalia, Nikolaevna Burova
AU - Emiliano, Renaldini
AU - Ioannis, Nanas
AU - Konstantin, Nikolayevich Zrazhevsky
AU - Ilidio, Moreira Joseà
AU - Giancarlo, Piovaccari
AU - Mariana, Radoi
AU - Valerii, Vladimirovich Batushkin
AU - Vira, Iosifovna Tseluiko
AU - Yuriy, Alexandrovich Vasyuk
AU - Grigory, Pavlovich Arutuynov
AU - Alexan, Nikolaevich Parkhomenko
AU - Leonid, Victorovich Rudenko
AU - Abdurrahman, Oğuzhan
AU - Mykola, Tihonovich Vatutin
AU - Pierfranco, Terrosu
AU - Roberto, Testa
AU - Quinto, Villani Giovanni
AU - Kayikcioglu, Meral
AU - Diaz, null
AU - Garcia, Alvés Mario
AU - Giovanni, Storti
AU - Roberto, Testa
AU - Vinereanu, Dragos
AU - Domenico, Cianflone
AU - Omboni, Stefano
AU - Patrizia, Presbitero
AU - Gaetano, De Ferrari
AU - Ambrosioni, Ettore
AU - Borghi, Claudio
PY - 2016
Y1 - 2016
N2 - Objective: In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods: The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results: A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofenopril significantly reduced the risk of hospitalization for cardiovascular causes in both nondiabetics [0.64 (0.43, 0.96), P = 0.030] and diabetics [0.38 (0.15, 0.95), P = 0.038], whereas it was not better than ramipril in terms of prevention of cardiovascular deaths. Conclusions: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril plus ASA in the prevention of long-term MACE also in the subgroup of patients with diabetes mellitus.
AB - Objective: In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods: The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results: A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofenopril significantly reduced the risk of hospitalization for cardiovascular causes in both nondiabetics [0.64 (0.43, 0.96), P = 0.030] and diabetics [0.38 (0.15, 0.95), P = 0.038], whereas it was not better than ramipril in terms of prevention of cardiovascular deaths. Conclusions: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril plus ASA in the prevention of long-term MACE also in the subgroup of patients with diabetes mellitus.
UR - http://hdl.handle.net/10447/298403
UR - http://www.blackwell-synergy.com/loi/CDR
M3 - Article
VL - 34
SP - 76
EP - 84
JO - Cardiovascular Therapeutics
JF - Cardiovascular Therapeutics
SN - 1755-5914
ER -